CA916798 gene expression is associated with multidrug resistance and predicts progression-free survival in patients with lung cancer

1Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

CA916798 has been identified as a novel multidrug resistance gene in lung cancer cells. However, the expression patterns of CA916798 in tumor tissues prior and subsequent to chemotherapy remain unclear. In the present study, CA916798 expression levels in tumor tissues prior and subsequent to chemotherapy were detected by reverse transcription-quantitative polymerase chain reaction and immunohistochemistry analysis. The prognostic significance of CA916798 expression in tumor tissues was explored by Kaplan-Meier survival analysis and Cox proportional hazards regression analysis. The messenger RNA (mRNA) and protein expression levels of CA916798 in tumor tissues were downregulated post-chemotherapy in chemotherapy-sensitive patients with lung cancer, but not in chemotherapy-resistant patients. Downregulation of CA916798 mRNA and protein expression post-chemotherapy was significantly associated with improved progression-free survival time. The findings from the present study suggest that platinum-based chemotherapy may induce the expression of CA916798, and CA916798 may be a promising biomarker to predict chemotherapy resistance and improve therapies for patients with lung cancer.

Cite

CITATION STYLE

APA

Duan, H., Yang, Z., Liang, L., & Zhou, X. (2019). CA916798 gene expression is associated with multidrug resistance and predicts progression-free survival in patients with lung cancer. Oncology Letters, 18(2), 1171–1178. https://doi.org/10.3892/ol.2019.10436

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free